leisure time -WSS

leisure time

author：comprehensive 2025-10-01 11:47:08 - browse：3

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

WSS

The nurse manager staffing crisis is hurting patients

Doulas covered by Medicaid under New York's new plan

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

The SUPPORT Act is critical to fighting the opioid crisis

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Generative AI mines health records to identify patients’ social needs

United colonoscopy coverage change 'may cost lives,' doctors say

Designating disabled people as health disparity population is crucial

Novavax promises a turnaround & Lilly roils the obesity market

Top private equity targets in 2023: cardiology, clinical trials, lasers

Psychedelics group wrestles with new pharma identity

Unique patient identifier: Experts argue the benefits, pitfalls

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

hotspot

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Bernie brings in new pharma CEOs to talk drug prices

A single Democrat is willing to weaken Medicare negotiation power

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Readout LOUD podcast: live from JPM 2024

Generative AI mines health records to identify patients’ social needs

hotspot

knowledge

Wikipedia

leisure time